Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



New Innovations in the Rapidly Growing U.S. Breast Cancer Pharmaceutical Market Finds Frost & Sullivan - As the second leading cause of death due to cancer in women, the pipeline for breast cancer therapeutics remains strong - Pharma.Frost.com
New Innovations in the Rapidly Growing U.S. Breast Cancer Pharmaceutical Market Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2012/05/16 - As the second leading cause of death due to cancer in women, the pipeline for breast cancer therapeutics remains strong - Pharma.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is currently an unmet need to treat patients. Consequently, there are abounding opportunities for pharmaceutical manufacturers, as breast cancer is the second most common cancer among women. There are currently 55 breast cancer therapeutic drugs in the developmental phase in the U.S., with additional drugs expected to enter this stage in the years to come.

New analysis from Frost & Sullivan’s (pharma.frost.com) A Product and Pipeline Analysis of the U.S. Breast Cancer Therapeutics Market research highlights the current market landscape, providing a competitive analysis of all marketed and pipeline drugs in this segment. Based on the research findings, Frost & Sullivan expects 24 drugs will launch for the treatment of breast cancer in the U.S. between 2012 and 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company Website, city, state and country.

The U.S. breast cancer therapeutics market is divided into four segments, including hormonal therapy, targeted therapy, chemotherapy and other therapy (for example, novel drugs in development). While approximately 70 percent of breast cancers qualify for hormonal therapy, there are only roughly seven hormonal therapies on the market for the treatment of breast cancer.

"Despite the current drugs on the market, there remain a number of unmet needs in the U.S. breast cancer therapeutics market," said Frost & Sullivan Life Sciences Global Program Manager Jennifer Brice. "For example, there are no antibody-based therapies approved for the treatment of breast cancer patients with low human epidermal growth factor receptor 2 (HER2) expression. In addition, the market is lacking HER2-targeted adjuvant treatment options to maintain disease-free status."

The next drug expected to hit the market is Eli Lilly’s IMC-1121B, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (MAb). This is a targeted treatment that identifies and attacks specific cancer cells without harming normal cells. In addition to VEGF, the only other targeted therapy is HER2-positive treatments. Of these two targeted therapy options, there are only two approved (non-antibody-based) treatments available in the U.S. market: Herceptin and Tykerb.

Market participants must ensure their breast cancer therapeutic treatments meet safety and regulatory stipulations. For example, Avastin (bevacizumab) was pulled from the market for treating advanced breast cancer due to safety risks. Additionally, targeted therapeutics for breast cancer can cause serious heart problems, such as heart attack, irregular heartbeats, decline in heart function, and in the most serious cases, death.

"Despite these safety concerns, treatment is a necessary function," said Brice. "This is particularly true for those diagnosed with breast cancer, so they may maintain a disease free status and survival."

A Product and Pipeline Analysis of the U.S. Breast Cancer Therapeutics Market is part of the Life Sciences Growth Partnership Service program, which also includes research in the following markets: Analysis of the United States Glaucoma Pharmaceuticals Market, Specialty Physicians Discuss their Opinions of the United States Biosimilars Market, Analysis of the United States Contract Manufacturing Outsourcing Market, Strategic Analysis of the U.S. Research Antibodies Market, and Analysis of the U.S. Clinical Laboratory Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation

A Product and Pipeline Analysis of the U.S. Breast Cancer Therapeutics Market.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Innovations in the Rapidly Growing U.S. Breast Cancer Pharmaceutical Market Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today